R.J. van Klaveren

1.2k citations
25 papers · 869 indexed · h-index 14
Topics
Lung Cancer Diagnosis and Treatment (12 papers)Lung Cancer Treatments and Mutations (12 papers)Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers)

In The Last Decade

R.J. van Klaveren

25 papers receiving 844 citations

Peers

R.J. van Klaveren
Comparison fields: 5 of 75
  • Pulmonary and Respiratory Medicine 718
  • Radiology, Nuclear Medicine and Imaging 237
  • Oncology 203
  • Radiation 108
  • Surgery 97
Replace Judi van Diessen with:
Judi van Diessen Netherlands
Peijin Han United States
J. McGuigan United Kingdom
Eliseo Passera Italy
Daniela Wagner Germany
Woo Kyung Chung South Korea
T Matsumoto Japan
Yasemin Bölükbaşı Türkiye
Fumihiko Hojo Japan
Aamir Khakwani United Kingdom
R.J. van Klaveren relative to Judi van Diessen Netherlands Judi van Diessen's profile →
Citations per field
00.5×3.6×
Judi van Diessen · 1×
Citations per year

Countries citing papers authored by R.J. van Klaveren

Since Specialization
Citations

This map shows the geographic impact of R.J. van Klaveren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.J. van Klaveren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.J. van Klaveren more than expected).

Fields of papers citing papers by R.J. van Klaveren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.J. van Klaveren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.J. van Klaveren. The network helps show where R.J. van Klaveren may publish in the future.

Co-authorship network of co-authors of R.J. van Klaveren

This figure shows the co-authorship network connecting the top 25 collaborators of R.J. van Klaveren. A scholar is included among the top collaborators of R.J. van Klaveren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.J. van Klaveren. R.J. van Klaveren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 38
2 18
3 36
4 102
5 71
6 131
7 1
8 19
9 6
10 3
11
A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC)
2
12 105
13 9
14 77
15 25
16 115
17 7
18 7
19 44
20 23

About R.J. van Klaveren

R.J. van Klaveren is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Biotechnology, having authored 25 papers that have together received 869 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (718 citations), Radiation (108 citations) and Radiology, Nuclear Medicine and Imaging (237 citations). R.J. van Klaveren has collaborated with scholars based in Netherlands, Belgium and Germany. Frequent co-authors include Harry J. de Koning, Karien A.M. van den Bergh, Carlijn M. van der Aalst, Marc C. Willemsen, Özcan Birim, A. Pieter Kappetein, Ad J.J.C. Bogers, Jan P. van Meerbeeck, Ernst T. Scholten and Marie‐Louise Essink‐Bot. Their work appears in journals such as Journal of Clinical Oncology, Gut and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026